191 related articles for article (PubMed ID: 32934818)
21. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
[TBL] [Abstract][Full Text] [Related]
22. Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
Ishida H; Iguchi A; Aoe M; Takahashi T; Tamefusa K; Kanamitsu K; Fujiwara K; Washio K; Matsubara T; Tsukahara H; Sanada M; Shimada A
Ann Hematol; 2019 Mar; 98(3):657-668. PubMed ID: 30446805
[TBL] [Abstract][Full Text] [Related]
23. Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.
Sexauer AN; Tasian SK
Front Pediatr; 2017; 5():248. PubMed ID: 29209600
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of Genetic Mutations in Korean Pediatric Acute Lymphoblastic Leukemia.
Yoo JW; Ahn A; Lee JM; Jo S; Kim S; Lee JW; Cho B; Kim Y; Kim M; Chung NG
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362526
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
27. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
28. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
29. Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients.
Gatua M; Navari M; Ong'ondi M; Onyango N; Kaggia S; Rogena E; Visani G; Abinya NA; Piccaluga PP
Front Genet; 2022; 13():843705. PubMed ID: 35836575
[TBL] [Abstract][Full Text] [Related]
30. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
31. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes.
Kim N; Hahn S; Choi YJ; Cho H; Chung H; Jang JE; Lyu CJ; Lee ST; Choi JR; Cheong JW; Shin S
Cancer Cell Int; 2024 May; 24(1):174. PubMed ID: 38764048
[TBL] [Abstract][Full Text] [Related]
33. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
34. [Pediatric acute myeloid leukemia with genetic alterations].
Shimada A
Rinsho Ketsueki; 2017; 58(8):983-990. PubMed ID: 28883284
[TBL] [Abstract][Full Text] [Related]
35.
Zhou JD; Yao DM; Li XX; Zhang TJ; Zhang W; Ma JC; Guo H; Deng ZQ; Lin J; Qian J
Oncotarget; 2017 Sep; 8(39):66087-66097. PubMed ID: 29029494
[TBL] [Abstract][Full Text] [Related]
36. Targeted Next-Generation Sequencing of Circulating Tumor DNA, Bone Marrow, and Peripheral Blood Mononuclear Cells in Pediatric AML.
Ruan M; Liu L; Qi B; Chen X; Chang L; Zhang A; Liu F; Wang S; Liu X; Chen X; Zhang L; Guo Y; Zou Y; Zhang Y; Chen Y; Liu L; Cao S; Lou F; Wang C; Zhu X
Front Oncol; 2021; 11():666470. PubMed ID: 34422630
[TBL] [Abstract][Full Text] [Related]
37. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
38. Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis.
Han X; Li W; He N; Feng P; Pang Y; Ji C; Ma D
Clin Chim Acta; 2018 Apr; 479():25-37. PubMed ID: 29309772
[TBL] [Abstract][Full Text] [Related]
39. Abnormalities of p51, p53, FLT3 and N-ras genes and their prognostic value in relapsed acute myeloid leukemia.
Nakamura H; Inokuchi K; Yamaguchi H; Dan K
J Nippon Med Sch; 2004 Aug; 71(4):270-8. PubMed ID: 15329487
[TBL] [Abstract][Full Text] [Related]
40. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
